Treatment of metastatic hormone‑dependent breast cancer with a combination of palbociclib and letrozole – case report
MUDr. Věra Benešová
Komplexní onkologické centrum, nemocnice Jihlava
The antitumor effect of cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors in combination with hormonal therapy significantly prolongs progression-free survival with prolonged lifespan. The use of this combination therapy in routine clinical practice is fundamentally changing the treatment options of our patients.
metastatic hormone-dependent breast cancer, palbociclib, letrozole
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...